MedTech 100 roundup: Stocks were practically unchanged last week

Despite plenty of ups and downs coming in the stock market for the medtech industry, there was hardly any movement from week to week.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.6 points at the end of last week (Aug. 21). Overall, medtech stocks saw a -0.2% decrease from the 89.77-point total at the same time a week prior (Aug. 14).

Once again, the index nearly reached a high point during the COVID-19 pandemic, as on Aug. 18, it hit 90.4 points for the second time in as many weeks, a total that nearly poked past the previous mid-pandemic high (90.45), which came on Aug. 5.

The most recent high mark represents just a -2.1% dip from the Feb. 19 high point of 92.32, while the tally at the end of the week marks a -2.9% decrease from that pre-pandemic high.

Meanwhile, the S&P 500 Index saw a 0.72% increase from Aug. 14 to Aug. 21, having reached record highs on Aug. 18. Meanwhil…

Read more
  • 0

FDA approves Cochlear sound processor

Cochlear Ltd. (ASX:COH) announced today that it received FDA approval for three new products in its suite of implantable hearing technology.

Lone Tree, Colo.-based Cochlear won approval for its Nucleus Kanso 2 sound processor, Nucleus 7 sound processor for Nucleus 22 implant recipients and Custom Sound Pro fitting software, according to a news release.

Cochlear touts the Kanso 2 sound processor as the world’s smallest off-the-ear cochlear implant sound processor and the only implant of its kind to offer direct streaming from compatible Apple for Android devices. It features new charging options and high water resistance in a durable, all-in-one design with button-free control and automatic on/off function.

The Nucleus 7 sound processor is now compatible with the Nucleus 22 implant — Cochlear’s first commercial implant — meaning recipients can upgrade to Cochlear’s latest behind-the-ear sound processor with direct smartphone connectivity…

Read more
  • 0

Cochlear wins FDA approval to lower age to implant to 9 months

Cochlear Ltd. (ASX:COH) has received FDA approval to lower the age of cochlear implantation to nine months for children.

The new approval lowers the age from the original 12 months for children with bilateral, profound sensorineural hearing loss.

Cochlear implants have been FDA approved for use in children since 1990.

“In light of all that has happened, access to hearing and hearing healthcare is more important now than ever. Hearing connects us to people and access to sound for those with hearing loss is important for connection as we continue to socially distance ourselves to mitigate this virus,” chief od audiology and research at Hearts of Hearing Jace Wolfe said in a news release. “For children especially, having access to sound during the important language development stages is critical. We know for children born with profound hearing loss, the earlier they receive cochlear implants, the greater their opportunity for success with…

Read more
  • 0